|Articles|October 1, 2001

Managed care organizations face crisis on many fronts

When Congress returned from its August recess after Labor Day, it lookedlike partisan politics combined with a national economic slowdown mightderail action on patients' rights legislation along with bills to reformthe Medicare+Choice program or establish a Medicare drug benefit. Democratsand Republicans were having trouble agreeing on spending programs, and interestgroups were squabbling over how to craft a fair pharmaceutical coverageprogram for seniors.

Newsletter

Get the latest industry news, event updates and more from Managed Healthcare Executive.

Subscribe

Latest CME

In-Person + Virtual Event

Medical Crossfire®: ADCs and Bispecifics in Lung Cancer – Hype, Hope, or a New Standard of Care?

September 12, 2026

Managed care organizations face crisis on many fronts

Related Content

Rural health is ailing. Is $50 billion enough to heal it?

States are stepping up healthcare oversight and regulation

Adverse drug events after hospitalization: 'These are the sickest people that we have who are not in the hospital'

Putting pharmacists in charge of medication management as patients leave the hospital seems like a good idea. Does it work?

The Great Healthcare Plan, MFN drug prices and the political implications of the end of ACA enhanced subsidies: Here are 7 takeaways from the MHE-AJMC webinar

Latest CME

Medical Crossfire®: ADCs and Bispecifics in Lung Cancer – Hype, Hope, or a New Standard of Care?

𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

27th Annual International Lung Cancer Congress®

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

26th Annual International Lung Cancer Congress

Tennessee Oncology Practice Society

Show Me the Data™: HER2-Mutant NSCLC in Transition — Translating Evidence to Practice

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Personalized Approaches in NSCLC: Early Detection, Molecular Testing, and Targeted Therapies

20th Annual New York Lung Cancers Symposium®

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

From Clue to Care: Rapid Recognition and Coordinated Management of Paraneoplastic LEMS in SCLC

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

(CPE Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Tumor Board: Translating HER2 and TROP2 Innovations to Transform NSCLC Care

Live Tumor Board: Precision Pathways Transforming Patient Care in Advanced NSCLC

Trending on Managed Healthcare Executive

Payer Implications and Final Takeaways from the BE BOLD Trial

A conversation with Tiffany Phung, Pharm.D., CSP, about how patient outcomes drive specialty pharmacy strategy

The biosimilars market is projected to nearly double — here's where the growth is coming from

Journavx helped most patients avoid opioids after surgery, a recent study found

Endometriosis increases the risk of Type 2 diabetes